MASLD Subtypes: Mayo Clinic Finds 5 Forms of Fatty Liver

Researchers at Mayo Clinic and Virginia Tech report that metabolic dysfunction-associated steatotic liver disease (MASLD), which affects nearly 30% of adults worldwide, may actually be five biologically distinct conditions. The subtypes differ in their associated risks of liver failure, cancer, heart disease, and the need for liver transplantation. The findings were published in Nature Communications and, if confirmed, could change how clinicians stratify risk in fatty liver disease.

What happened

The team analyzed genetic sequencing results together with detailed clinical data from more than 4,600 patients diagnosed with MASLD. The clinical data included liver enzymes, body mass index, blood lipid levels, and other markers of metabolic health. The researchers also looked at comorbid conditions such as diabetes, depression, and sleep apnea.

Using advanced computer models, they searched for patterns linking patients with similar genetic and clinical features. This produced five distinct groups, each with its own underlying biological characteristics. According to the investigators, MASLD can develop through several different pathways. Some subtypes are closely tied to obesity and diabetes, while others appear to be driven by inherited genetic differences.

The genetic subtypes stood out. They were associated with a greater likelihood of progressing to advanced liver damage, even in people who lack the metabolic risk factors usually linked to fatty liver.

The data came from Mayo Clinic's Research Data Atlas, which links genetic information to detailed medical records. It draws on resources such as the Tapestry Study, Mayo's largest exome collection, with more than 100,000 participants.

The researchers also reported associations between certain subtypes and depression, sleep apnea, and migraine. They stress that this does not show fatty liver disease causes these conditions.

Why it matters

Today, a patient with hepatic steatosis and metabolic risk factors gets one label, and risk assessment is mostly generic. Yet clinicians know that some patients with fatty liver stay stable for decades while others progress to cirrhosis. MASLD is a major contributor to cirrhosis, liver cancer, and liver transplantation worldwide, so explaining that variability matters.

If subtypes hold up, they could help in three ways:

• Earlier recognition of vulnerable patients, including those with few conventional risk factors.
• Better screening, directed at people with higher-risk biology.
• Treatment matched to mechanism, rather than one approach for everyone.

The authors plan to test the findings in larger and more diverse populations. They also want to see whether subtypes respond differently to available treatments, including GLP-1 receptor agonists. None of this is established yet.

What to know for the USMLE

The study itself is not a test topic, but it sits on top of material that is. Here is the high-yield background.

• Nomenclature: MASLD is the newer term for NAFLD. It means hepatic steatosis (fat in more than about 5% of hepatocytes) plus at least one cardiometabolic risk factor, such as obesity, type 2 diabetes, hypertension, or dyslipidemia. MASH (formerly NASH) is the inflammatory form. Older question stems may still say NAFLD/NASH.
• Pathogenesis: Insulin resistance is central. It increases adipose tissue lipolysis, so more free fatty acids reach the liver. It also drives hepatic de novo lipogenesis. Excess lipid causes lipotoxicity, oxidative stress, and inflammation. Activated hepatic stellate cells then lay down collagen, leading to fibrosis.
• Histology: Look for macrovesicular steatosis, usually centrilobular at first. In MASH, add hepatocyte ballooning, lobular inflammation, and sometimes Mallory-Denk bodies and perisinusoidal ("chicken-wire") fibrosis. Fibrosis stage is the strongest predictor of outcomes.
• Genetics: The study reports inherited subtypes without naming genes in the source material. As background, the classic textbook association is PNPLA3 (I148M), which increases susceptibility to steatosis and progression. TM6SF2 variants are also linked to fatty liver. This is why a patient with a normal BMI can still develop advanced disease.
• Labs: Mild elevation of ALT and AST is typical, with ALT often greater than AST. An AST:ALT ratio above 2 points toward alcohol-associated liver disease.
• Evaluation: Ultrasound shows a hyperechoic liver. Noninvasive fibrosis scores such as FIB-4 and transient elastography are used to risk-stratify. Biopsy remains the gold standard for diagnosing MASH.
• Complications: Progression runs from steatosis to MASH, fibrosis, cirrhosis (portal hypertension, ascites, varices, encephalopathy), and hepatocellular carcinoma (HCC). HCC can occasionally arise in MASLD even without cirrhosis.
• Cardiometabolic link: Cardiovascular disease is a leading cause of death in patients with fatty liver, which is why the subtypes' different heart disease risks are notable. Also remember the association with obstructive sleep apnea, which the study also reports.
• Management principles: Lifestyle-driven weight loss is foundational. Control of diabetes and lipids is also part of care. Drug options have been expanding, including thyroid hormone receptor-β agonists and GLP-1 receptor agonists, and exam questions are increasingly likely to mention them. Check current guidelines for the details.

Limitations

Read this study for what it is: a data-driven classification, not a treatment trial.

• The source material describes associations. It does not show that any subtype causes complications, and it explicitly says the links to depression, sleep apnea, and migraine do not prove causation.
• The five subtypes came from computer models applied to one set of patients (more than 4,600). The authors still plan to test them in larger and more diverse populations, so generalizability is unknown.
• The source does not say whether subtypes can be identified in routine practice. Genetic sequencing is not part of standard fatty liver workups today.
• Whether subtypes respond differently to treatment, including GLP-1 receptor agonists, is an open question and has not been shown.
• The article is based on a press release, so details such as the exact features of each subtype are not covered here. Consult the original paper for those.

For exam purposes, current guidelines and standard pathophysiology still apply. This research is a preview of where risk stratification may go.

FAQ

What is the difference between MASLD and NAFLD?

MASLD is the updated name for NAFLD. It emphasizes the metabolic cause of the disease, defining it as hepatic steatosis plus at least one cardiometabolic risk factor, rather than a diagnosis of exclusion. The disease is the same one, now described with more positive criteria and less stigmatizing language.

Does the Mayo Clinic study change how MASLD is diagnosed?

Not yet. The researchers suggest subtypes could eventually support earlier recognition, better screening, and tailored treatment. But the findings still need testing in larger, more diverse groups, and no subtype-based clinical pathway has been established.

Why can a person without obesity or diabetes still develop advanced fatty liver disease?

According to the study, some subtypes appear to be driven by inherited genetic differences rather than by obesity or diabetes. These genetic forms were associated with a higher likelihood of progressing to advanced liver damage even in people without typical metabolic risk factors. In USMLE terms, think of PNPLA3 as the classic example of a genetic modifier of fatty liver risk.

Key takeaways

• Mayo Clinic and Virginia Tech researchers used genetic and clinical data from over 4,600 MASLD patients to identify five biologically distinct subtypes with different risks of liver failure, cancer, heart disease, and transplant.
• Genetic subtypes were linked to advanced liver disease even without usual metabolic risk factors. The findings are associations, still need validation in larger and more diverse populations, and are not yet changing clinical practice.
• For USMLE, focus on the fundamentals: insulin resistance, MASLD to MASH to cirrhosis to HCC, PNPLA3, histology, and the cardiometabolic connections.